magnetic beads coated with tumor immunophenotype-specific antibodies easysep® positive selection kits (STEMCELL Technologies Inc)
90
Structured Review
STEMCELL Technologies Inc
magnetic beads coated with tumor immunophenotype-specific antibodies easysep® positive selection kits
Magnetic Beads Coated With Tumor Immunophenotype Specific Antibodies Easysep® Positive Selection Kits, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/magnetic+beads+coated+with+tumor+immunophenotype-specific+antibodies+easysep%C2%AE+positive+selection+kits/magnetic+beads+coated+with+tumor+immunophenotype+specific+antibodies+easysep++positive+selection+kits/pm33070150-12-32-39
Average 90 stars, based on 1 article reviews
Magnetic Beads Coated With Tumor Immunophenotype Specific Antibodies Easysep® Positive Selection Kits, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/magnetic+beads+coated+with+tumor+immunophenotype-specific+antibodies+easysep%C2%AE+positive+selection+kits/magnetic+beads+coated+with+tumor+immunophenotype+specific+antibodies+easysep++positive+selection+kits/pm33070150-12-32-39
Average 90 stars, based on 1 article reviews
magnetic beads coated with tumor immunophenotype-specific antibodies easysep® positive selection kits - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Selection:Article Title: HLA-haplotype loss after TCRαβ/CD19-depleted haploidentical HSCT. Article Snippet: Genomic loss of the mismatched HLA haplotype (i.e. HLA loss) was first described nearly 10 years ago in adult patients with myeloid malignancies undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) [1].. A follow-up study examined patients with myeloid malignancies undergoing HLA-mismatched HSCT from either related or unrelated donors found that HLA loss accounted for 33% of disease recurrence in patients receiving haplo-HSCT, demonstrating a recurring mechanism of post mismatched HSCT relapse [2].. Other smaller case reports in adults affected by lymphoid malignancies receiving mismatched HSCT showed a similar incidence of HLA. Magnetic Beads:Article Title: HLA-haplotype loss after TCRαβ/CD19-depleted haploidentical HSCT. Article Snippet: Genomic loss of the mismatched HLA haplotype (i.e. HLA loss) was first described nearly 10 years ago in adult patients with myeloid malignancies undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) [1].. A follow-up study examined patients with myeloid malignancies undergoing HLA-mismatched HSCT from either related or unrelated donors found that HLA loss accounted for 33% of disease recurrence in patients receiving haplo-HSCT, demonstrating a recurring mechanism of post mismatched HSCT relapse [2].. Other smaller case reports in adults affected by lymphoid malignancies receiving mismatched HSCT showed a similar incidence of HLA. |